Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?

Nature Clinical Practice Oncology volume 5, pages 130–131 (2008)Cite this article

boxed-textChauvenet AR et al. (2007) Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 110: 1105–1111

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pui CH and Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354: 166–178

    Article  CAS  Google Scholar 

  2. Chauvenet AR et al. (2007) Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood 110: 1105–1111

    Article  CAS  Google Scholar 

  3. Pui CH et al. (2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104: 2690–2696

    Article  CAS  Google Scholar 

  4. Bo J et al. (1999) Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 86: 1080–1086

    Article  CAS  Google Scholar 

  5. Relling MV et al. (2006) Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107: 843–844

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Helen Jaques, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. C-H Pui is Chair of the Department of Oncology, WE Evans is the Director and Chief Executive Officer and MV Relling is Chair of the Department of Pharmaceutical Science, St Jude Children's Research Hospital, Memphis, TN, USA.,

    Ching-Hon Pui, William E Evans & Mary V Relling

Authors
  1. Ching-Hon Pui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William E Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary V Relling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ching-Hon Pui.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pui, CH., Evans, W. & Relling, M. Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?. Nat Rev Clin Oncol 5, 130–131 (2008). https://doi.org/10.1038/ncponc1035

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1035

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing